Table 6.
Suggested therapy for aflatoxicosis treatment in dogs *.
| Drug | Dose | Administration via | Usual Interval (h/d) | Therapeutic Indications |
|---|---|---|---|---|
| Hemostatic Stabilization | ||||
| Vitamin K1 | 2.0 mg/kg | SC | 24/5 | Synthesis of coagulation factors |
| Intravenous plasma | 10.0 mL/kg | IV | Until TP & TTPa are restored | Correction of coagulopathy |
| Elimination of AF and Hepato-Renal Protection | ||||
| Hartman solution | 40.0–60.0 mL/kg/d | IV | cbp | Increased glomerular filtration rate and restoration of water/electrolyte balance |
| N-acetylcysteine | 70.0 mg/kg | IV | 12/15 | GSH synthesis and AF binding |
| Silymarin | 20 mg/kg | PO | 24/30 | Counter AF epoxides |
| Vitamin E | 10.0 U/kg | PO | 24/30 | Counter AF epoxides |
| L-carnitine | 50.0–100 mg/kg | PO | 8/30 | Decreased liver lipidosis and counter epoxides |
| Symptomatic Treatment | ||||
| Metoclopramide | 0.40 mg/kg | SC | 8/3 | Antiemetic |
| Ondansetron | 0.15 mg/kg | IV | 12/3 | Antiemetic |
| Famotidine | 0.5 mg/kg | IV | 12/30 | Decreased gastric secretion |
| Sucralfate | 0.5–1.0 g/dog | PO | 8/30 | Gastric cytoprotection |
| Ampicillin | 25.0 mg/kg | IV | 8/7 | Broad spectrum bactericide |
| Enrofloxacin | 5.0–20.0 mg/kg | IV | 12/7 días | Broad spectrum bactericide |